Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
SuperBuzz: Die KI-Aktie, die man sich jetzt zum Ende des Sommers nicht entgehen lassen darf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ALUN | ISIN: SE0008241491 | Ticker-Symbol: 8F8
Frankfurt
29.08.25 | 15:29
1,570 Euro
-0,38 % -0,006
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SYNACT PHARMA AB Chart 1 Jahr
5-Tage-Chart
SYNACT PHARMA AB 5-Tage-Chart

Aktuelle News zur SYNACT PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.08.SynAct Pharma AB: SynAct Pharma publishes Q2 2025 interim results120SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2025. "SynAct continued to strengthen its position during the second quarter, refining its development strategy...
► Artikel lesen
27.05.SynAct Pharma AB: SynAct Pharma publishes Q1 2025 interim results148SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2025. "SynAct Pharma has a remarkable drug candidate with resomelagon (AP1189). The data gained so far point...
► Artikel lesen
SYNACT PHARMA Aktie jetzt für 0€ handeln
12.05.SynAct Pharma AB: SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy310SynAct Pharma AB (publ) ("SynAct") announced today that the Unites States Patent and Trademark Office (USPTO) has provided the issue notification of US patent 12,303,489 with issue date 20 May 2025...
► Artikel lesen
23.04.SynAct Pharma secures patent for resomelagon in combination with MTX1
23.04.SynAct Pharma AB: SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy155SynAct Pharma AB (publ) ("SynAct") announced today that the Unites States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application US 17/609,849 with claims covering...
► Artikel lesen
14.04.SynAct Pharma's resomelagon under clinical evaluation for dengue1
11.04.SynAct Pharma AB: SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue191SynAct Pharma AB ("SynAct Pharma") today announced that the RESOVIR-2 study, an exploratory Phase 2 trial to evaluate the safety and efficacy of the company's lead candidate drug resomelagon (AP1189)...
► Artikel lesen
06.03.SynAct Pharma secures key US patent2
18.02.SynAct Pharma AB: SynAct Pharma Year-end Report 2024186SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2024. "SynAct Pharma was running at full speed during the fourth quarter. The team has done a fantastic job ensuring our Phase...
► Artikel lesen
13.12.24SynAct Pharma AB: Bulletin from the extraordinary general meeting of SynAct Pharma AB179Today, on 13 December 2024, an extraordinary general meeting of SynAct Pharma AB ("SynAct Pharma" or the "Company") was held in Stockholm. The general meeting resolved on three directed share issues...
► Artikel lesen
13.12.24XFRA CAPITAL ADJUSTMENT INFORMATION - 13.12.20241.652Das Instrument 84L0 CA0967751011 BOBA MINT HLDGS LTD EQUITY wird cum Kapitalmassnahme gehandelt am 13.12.2024 und ex Kapitalmassnahme am 16.12.2024 The instrument 84L0 CA0967751011 BOBA MINT HLDGS LTD...
► Artikel lesen
30.10.24SynAct Pharma AB: SynAct Pharma publishes Q3 2024 interim results128SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the third quarter 2024 and first nine months. "The SynAct team continued to work focused during the third quarter as the company...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1